Gyre Therapeutics appoints three new board members

Management
โดย GlobeNewswire·Read original
Summary · why it matters

Gyre Therapeutics has appointed three new members to its board of directors, effective August 1, 2026. The new directors are Chief Scientific Officer Yue Xiong, Maxwell Kirkby, and Claire Weston. Dr. Xiong will serve as a Class I director with a term expiring in 2028, Mr. Kirkby as a Class II director with a term expiring in 2029 and a seat on the Compensation Committee, and Dr. Weston as a Class III director with a term expiring in 2027 and a seat on the Audit Committee. The company stated the appointments expand its scientific, clinical development, and cross-border biopharmaceutical operating expertise as it advances its pipeline targeting fibrosis, cancer, inflammation, and pain.

Impact on stocks 1

Health Care▲ · 1 stocks
Gyre Therapeutics Inc.
GYRE
▲ PositiveCapitalrelevance

Appointment of three new board members with relevant expertise to advance pipeline.

© 2026 MarketDXNews